Yen-Liang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yen-Liang Chen has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
Fumiaki Yokokawa
Novartis Institute for Tropical Diseases, Singapore
4 shared publicationsPei-Yong Shi
Novartis Institute for Tropical Diseases, Singapore
4 shared publications- Siew Pheng Lim
Novartis Institute for Tropical Diseases, Singapore
4 shared publications - Srinivasa P. S. Rao
Global Health, Biomedical Research, Novartis
4 shared publications Francesca Blasco
Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
3 shared publicationsGang Wang
Novartis Institute for Tropical Diseases, Singapore 138670, Singapore
3 shared publications
Latest Publications
- Open Access
- 9 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (37)
IID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model
Chagas disease is a neglected disease that affects millions of people from the Latin American region. Current nitroheterocyclic therapies suffer from long treatment duration and safety-related treatment discontinuations. A safe, short course therapy would significantly benefit Chagas patients. Here, we report the comprehensive biological, structural, pharmacodynamic, and pharmacokinetic characterization of IID432, an optimized cyanotriazole with superior potency, favorable pharmacokinetics, and improved safety profile compared to the lead compound CT1. IID432 is a fast-acting, parasite-selective topoisomerase II poison that achieves sterile cure after a single oral dose in a murine model of chronic Trypanosoma cruzi infection. Mechanistically, IID432 stabilizes the parasite TcTopoII-DNA cleavage complex by covalently engaging a parasite-specific cysteine (Cys477), thereby conferring selectivity over the human TOP2A. IID432 displays favorable oral pharmacokinetics, with no off-target activity on human topoisomerases. Brief exposure of IID432 rapidly induces parasite-specific DNA damage and produces sterilizing activity in vitro and in vivo without recrudescence. Together, these findings identify IID432 as a first-in-class, parasite-selective covalent topoisomerase poison with a potential to significantly shorten treatment duration for T. cruzi infections.
- 9 September 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (37)
Open AccessIID432, a parasite-selective topoisomerase II inhibitor, achieves rapid single-dose parasite clearance in a murine chronic Chagas model
Chagas disease is a neglected disease that affects millions of people from the Latin American region. Current nitroheterocyclic therapies suffer from long treatment duration and safety-related treatment discontinuations. A safe, short course therapy would significantly benefit Chagas patients. Here, we report the comprehensive biological, structural, pharmacodynamic, and pharmacokinetic characterization of IID432, an optimized cyanotriazole with superior potency, favorable pharmacokinetics, and improved safety profile compared to the lead compound CT1. IID432 is a fast-acting, parasite-selective topoisomerase II poison that achieves sterile cure after a single oral dose in a murine model of chronic Trypanosoma cruzi infection. Mechanistically, IID432 stabilizes the parasite TcTopoII-DNA cleavage complex by covalently engaging a parasite-specific cysteine (Cys477), thereby conferring selectivity over the human TOP2A. IID432 displays favorable oral pharmacokinetics, with no off-target activity on human topoisomerases. Brief exposure of IID432 rapidly induces parasite-specific DNA damage and produces sterilizing activity in vitro and in vivo without recrudescence. Together, these findings identify IID432 as a first-in-class, parasite-selective covalent topoisomerase poison with a potential to significantly shorten treatment duration for T. cruzi infections.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6652) , 1349-1356
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections
Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo–electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.
- 30 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 380 (6652) , 1349-1356
Cyanotriazoles are selective topoisomerase II poisons that rapidly cure trypanosome infections
Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo–electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.
- 3 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (579)
NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models
NITD-688, a pan-serotype dengue virus inhibitor, is effective in mice and is well tolerated with favorable pharmacokinetics in animal models.
- 3 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (579)
NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models
NITD-688, a pan-serotype dengue virus inhibitor, is effective in mice and is well tolerated with favorable pharmacokinetics in animal models.
- 23 November 2020
- Published by American Society for Microbiology in Journal of Virology
- Vol. 94 (24)
Two RNA Tunnel Inhibitors Bind in Highly Conserved Sites in Dengue Virus NS5 Polymerase: Structural and Functional Studies
Dengue virus (DENV) NS5 RNA-dependent RNA polymerase (RdRp), an important drug target, synthesizes viral RNA and is essential for viral replication. Whilst a number of allosteric inhibitors have been reported for Hepatitis C virus RdRp, few have been described for DENV RdRp. Following a diverse compound screening campaign and a rigorous hit-to-lead flow-chart combining biochemical and biophysical approaches, two DENV RdRp non-nucleoside inhibitors were identified and characterized. These inhibitors show low to high micro-molar inhibition in DENV RNA polymerization and cell-based assays. X-ray crystallography reveals that they bind in the enzyme RNA template tunnel. One compound (NITD-434) induced an allosteric pocket at the junction of the fingers and palm subdomains by displacing residue V603 in motif B. Binding of another compound (NITD-640) ordered the fingers loop preceding the F motif, close to the RNA template entrance. Most of the amino acid residues that interacted with these compounds are highly conserved in flaviviruses. Both sites are important for polymerase de novo initiation and elongation activities and essential for viral replication. This work provides evidence that the RNA tunnel in DENV RdRp offers interesting target sites for inhibition. IMPORTANCE Dengue virus (DENV), an important arthropod-transmitted human pathogen that causes a spectrum of diseases, has spread dramatically worldwide in recent years. Despite extensive efforts, the only commercial vaccine does not provide adequate protection to naïve individuals. DENV NS5 polymerase is a promising drug target, as exemplified by the development of successful commercial drugs against HCV polymerase and HIV-1 reverse transcriptase. High-throughput screening of compound libraries against this enzyme enabled the discovery of inhibitors that induced binding sites in the RNA template channel. Characterization by biochemical, biophysical and reverse genetics approaches provide a better understanding of the biological relevance of these allosteric sites and the way forward to design more potent inhibitors.
- 23 November 2020
- Published by American Society for Microbiology in Journal of Virology
- Vol. 94 (24)
Two RNA Tunnel Inhibitors Bind in Highly Conserved Sites in Dengue Virus NS5 Polymerase: Structural and Functional Studies
Dengue virus (DENV) NS5 RNA-dependent RNA polymerase (RdRp), an important drug target, synthesizes viral RNA and is essential for viral replication. Whilst a number of allosteric inhibitors have been reported for Hepatitis C virus RdRp, few have been described for DENV RdRp. Following a diverse compound screening campaign and a rigorous hit-to-lead flow-chart combining biochemical and biophysical approaches, two DENV RdRp non-nucleoside inhibitors were identified and characterized. These inhibitors show low to high micro-molar inhibition in DENV RNA polymerization and cell-based assays. X-ray crystallography reveals that they bind in the enzyme RNA template tunnel. One compound (NITD-434) induced an allosteric pocket at the junction of the fingers and palm subdomains by displacing residue V603 in motif B. Binding of another compound (NITD-640) ordered the fingers loop preceding the F motif, close to the RNA template entrance. Most of the amino acid residues that interacted with these compounds are highly conserved in flaviviruses. Both sites are important for polymerase de novo initiation and elongation activities and essential for viral replication. This work provides evidence that the RNA tunnel in DENV RdRp offers interesting target sites for inhibition. IMPORTANCE Dengue virus (DENV), an important arthropod-transmitted human pathogen that causes a spectrum of diseases, has spread dramatically worldwide in recent years. Despite extensive efforts, the only commercial vaccine does not provide adequate protection to naïve individuals. DENV NS5 polymerase is a promising drug target, as exemplified by the development of successful commercial drugs against HCV polymerase and HIV-1 reverse transcriptase. High-throughput screening of compound libraries against this enzyme enabled the discovery of inhibitors that induced binding sites in the RNA template channel. Characterization by biochemical, biophysical and reverse genetics approaches provide a better understanding of the biological relevance of these allosteric sites and the way forward to design more potent inhibitors.
- 17 November 2020
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (12)
A Cyclic Phosphoramidate Prodrug of 2′-Deoxy-2′-Fluoro-2′- C -Methylguanosine for the Treatment of Dengue Virus Infection
Monophosphate prodrug analogs of 2′-deoxy-2′-fluoro-2′- C -methylguanosine have been reported as potent inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase. These prodrugs also display potent anti-dengue virus activities in cellular assays although their prodrug moieties were designed to produce high levels of triphosphate in the liver. Since peripheral blood mononuclear cells (PBMCs) are among the major targets of dengue virus, different prodrug moieties were designed to effectively deliver 2′-deoxy-2′-fluoro-2′- C -methylguanosine monophosphate prodrugs and their corresponding triphosphates into PBMCs after oral administration.
- 17 November 2020
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (12)
A Cyclic Phosphoramidate Prodrug of 2′-Deoxy-2′-Fluoro-2′- C -Methylguanosine for the Treatment of Dengue Virus Infection
Monophosphate prodrug analogs of 2′-deoxy-2′-fluoro-2′- C -methylguanosine have been reported as potent inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase. These prodrugs also display potent anti-dengue virus activities in cellular assays although their prodrug moieties were designed to produce high levels of triphosphate in the liver. Since peripheral blood mononuclear cells (PBMCs) are among the major targets of dengue virus, different prodrug moieties were designed to effectively deliver 2′-deoxy-2′-fluoro-2′- C -methylguanosine monophosphate prodrugs and their corresponding triphosphates into PBMCs after oral administration.
- 13 July 2020
- Published by Springer Nature in Nature Microbiology
- Vol. 5 (10) , 1207-1216
Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors
The kinetochore is a macromolecular structure that assembles on the centromeres of chromosomes and provides the major attachment point for spindle microtubules during mitosis. In Trypanosoma brucei, the proteins that make up the kinetochore are highly divergent; the inner kinetochore comprises at least 20 distinct and essential proteins (KKT1–20) that include four protein kinases—CLK1 (also known as KKT10), CLK2 (also known as KKT19), KKT2 and KKT3. Here, we report the identification and characterization of the amidobenzimidazoles (AB) protein kinase inhibitors that show nanomolar potency against T. brucei bloodstream forms, Leishmania and Trypanosoma cruzi. We performed target deconvolution analysis using a selection of 29 T. brucei mutants that overexpress known essential protein kinases, and identified CLK1 as a primary target. Biochemical studies and the co-crystal structure of CLK1 in complex with AB1 show that the irreversible competitive inhibition of CLK1 is dependent on a Michael acceptor forming an irreversible bond with Cys 215 in the ATP-binding pocket, a residue that is not present in human CLK1, thereby providing selectivity. Chemical inhibition of CLK1 impairs inner kinetochore recruitment and compromises cell-cycle progression, leading to cell death. This research highlights a unique drug target for trypanosomatid parasitic protozoa and a new chemical tool for investigating the function of their divergent kinetochores.
- 13 July 2020
- Published by Springer Nature in Nature Microbiology
- Vol. 5 (10) , 1207-1216
Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors
The kinetochore is a macromolecular structure that assembles on the centromeres of chromosomes and provides the major attachment point for spindle microtubules during mitosis. In Trypanosoma brucei, the proteins that make up the kinetochore are highly divergent; the inner kinetochore comprises at least 20 distinct and essential proteins (KKT1–20) that include four protein kinases—CLK1 (also known as KKT10), CLK2 (also known as KKT19), KKT2 and KKT3. Here, we report the identification and characterization of the amidobenzimidazoles (AB) protein kinase inhibitors that show nanomolar potency against T. brucei bloodstream forms, Leishmania and Trypanosoma cruzi. We performed target deconvolution analysis using a selection of 29 T. brucei mutants that overexpress known essential protein kinases, and identified CLK1 as a primary target. Biochemical studies and the co-crystal structure of CLK1 in complex with AB1 show that the irreversible competitive inhibition of CLK1 is dependent on a Michael acceptor forming an irreversible bond with Cys 215 in the ATP-binding pocket, a residue that is not present in human CLK1, thereby providing selectivity. Chemical inhibition of CLK1 impairs inner kinetochore recruitment and compromises cell-cycle progression, leading to cell death. This research highlights a unique drug target for trypanosomatid parasitic protozoa and a new chemical tool for investigating the function of their divergent kinetochores.
- Open Access
A Cyclic Phosphoramidate Prodrug of 2’-deoxy-2’-fluoro-2’-C-methylguanosine for the Treatment of Dengue Infection
Monophosphate prodrug analogs of 2’-deoxy-2’-fluoro-2’-C-methylguanosine have been reported as potent inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase. These prodrugs also display potent anti-dengue activities in cellular assays although their prodrug moieties were designed to produce high levels of triphosphate in the liver. Since peripheral blood mononuclear cells (PBMCs) are one of the major targets of dengue virus, different prodrug moieties were designed to effectively deliver 2’-deoxy-2’-fluoro-2’-C-methylguanosine monophosphate prodrugs and their corresponding triphosphates into PBMCs after oral administration. We identified a cyclic phosphoramidate prodrug 17 demonstrating a well-balanced anti-dengue cellular activity and in vitro stability profiles. In dogs, oral administration of 17 resulted in high PBMC triphosphate level, exceeding TP 50 (the intracellular triphosphate concentration at which 50% of virus replication is inhibited) at 10 mg/kg. Compound 17 demonstrated 1.6- and 2.2 log viremia reduction in the dengue mouse model at 100 and 300 mg/kg twice daily, respectively. At 100 mg/kg twice daily, the terminal triphosphate concentration in PBMCs reached above TP 50 , defining for the first time the minimum efficacious dose for a nucleos(t)ide prodrug. In the two-week dog toxicity studies at 30 to 300 mg/kg/day, no observed adverse effect level (NOAEL) could not be achieved due to pulmonary inflammation and hemorrhage. The preclinical safety results suspended further development of 17. Nevertheless, present work has proven the concept that an efficacious monophosphate nucleoside prodrug could be developed for the potential treatment of dengue infection.
Open AccessA Cyclic Phosphoramidate Prodrug of 2’-deoxy-2’-fluoro-2’-C-methylguanosine for the Treatment of Dengue Infection
Monophosphate prodrug analogs of 2’-deoxy-2’-fluoro-2’-C-methylguanosine have been reported as potent inhibitors of hepatitis C virus (HCV) RNA-dependent RNA polymerase. These prodrugs also display potent anti-dengue activities in cellular assays although their prodrug moieties were designed to produce high levels of triphosphate in the liver. Since peripheral blood mononuclear cells (PBMCs) are one of the major targets of dengue virus, different prodrug moieties were designed to effectively deliver 2’-deoxy-2’-fluoro-2’-C-methylguanosine monophosphate prodrugs and their corresponding triphosphates into PBMCs after oral administration. We identified a cyclic phosphoramidate prodrug 17 demonstrating a well-balanced anti-dengue cellular activity and in vitro stability profiles. In dogs, oral administration of 17 resulted in high PBMC triphosphate level, exceeding TP 50 (the intracellular triphosphate concentration at which 50% of virus replication is inhibited) at 10 mg/kg. Compound 17 demonstrated 1.6- and 2.2 log viremia reduction in the dengue mouse model at 100 and 300 mg/kg twice daily, respectively. At 100 mg/kg twice daily, the terminal triphosphate concentration in PBMCs reached above TP 50 , defining for the first time the minimum efficacious dose for a nucleos(t)ide prodrug. In the two-week dog toxicity studies at 30 to 300 mg/kg/day, no observed adverse effect level (NOAEL) could not be achieved due to pulmonary inflammation and hemorrhage. The preclinical safety results suspended further development of 17. Nevertheless, present work has proven the concept that an efficacious monophosphate nucleoside prodrug could be developed for the potential treatment of dengue infection.
- 1 October 2015
- Published by Elsevier in Antiviral Research
- Vol. 122, 12-19
The search for nucleoside/nucleotide analog inhibitors of dengue virus
- 1 October 2015
- Published by Elsevier in Antiviral Research
- Vol. 122, 12-19
The search for nucleoside/nucleotide analog inhibitors of dengue virus
- Open Access
- 1 April 2015
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (4) , 2086-2093
Synergistic Suppression of Dengue Virus Replication Using a Combination of Nucleoside Analogs and Nucleoside Synthesis Inhibitors
Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. Currently, there is no clinically approved vaccine or antiviral for DENV. Combination therapy is a common practice in antiviral treatment and a potential approach to search for new treatments for infectious pathogens. In this study, we performed a combination treatment in cell culture by using three distinct classes of inhibitors, including ribavirin (a guanosine analog with several antiviral mechanisms), brequinar (a pyrimidine biosynthesis inhibitor), and INX-08189 (a guanosine analog). The compound pairs were evaluated for antiviral activity by use of a DENV-2 luciferase replicon assay. Our result indicated that the combination of ribavirin and INX-08189 exhibited strong antiviral synergy. This result suggests that synergy can be achieved with compound pairs in which one compound suppresses the synthesis of the nucleoside for which the other compound is a corresponding nucleoside analog. In addition, we found that treatment of cells with brequinar alone could activate interferon-stimulated response elements (ISREs); furthermore, brequinar and NITD-982 (another pyrimidine biosynthesis inhibitor) potentiated interferon-induced ISRE activation. Compared to treatment with brequinar, treatment of cells with ribavirin alone could also induce ISRE activation, but to a lesser extent; however, when cells were cotreated with ribavirin and beta interferon, ribavirin did not augment the interferon-induced ISRE activation.
- 1 April 2015
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 59 (4) , 2086-2093
Open AccessSynergistic Suppression of Dengue Virus Replication Using a Combination of Nucleoside Analogs and Nucleoside Synthesis Inhibitors
Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen in humans. Currently, there is no clinically approved vaccine or antiviral for DENV. Combination therapy is a common practice in antiviral treatment and a potential approach to search for new treatments for infectious pathogens. In this study, we performed a combination treatment in cell culture by using three distinct classes of inhibitors, including ribavirin (a guanosine analog with several antiviral mechanisms), brequinar (a pyrimidine biosynthesis inhibitor), and INX-08189 (a guanosine analog). The compound pairs were evaluated for antiviral activity by use of a DENV-2 luciferase replicon assay. Our result indicated that the combination of ribavirin and INX-08189 exhibited strong antiviral synergy. This result suggests that synergy can be achieved with compound pairs in which one compound suppresses the synthesis of the nucleoside for which the other compound is a corresponding nucleoside analog. In addition, we found that treatment of cells with brequinar alone could activate interferon-stimulated response elements (ISREs); furthermore, brequinar and NITD-982 (another pyrimidine biosynthesis inhibitor) potentiated interferon-induced ISRE activation. Compared to treatment with brequinar, treatment of cells with ribavirin alone could also induce ISRE activation, but to a lesser extent; however, when cells were cotreated with ribavirin and beta interferon, ribavirin did not augment the interferon-induced ISRE activation.
- 18 October 2013
- Published by Elsevier in Journal of Virological Methods
- Vol. 196, 18-24
Development of a FACS-based assay for evaluating antiviral potency of compound in dengue infected peripheral blood mononuclear cells
- 18 October 2013
- Published by Elsevier in Journal of Virological Methods
- Vol. 196, 18-24
Development of a FACS-based assay for evaluating antiviral potency of compound in dengue infected peripheral blood mononuclear cells